Prothena

PRTA · NASDAQ

$8.50+$0.02 (+0.24%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $8.48

About PRTA

Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The firm is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.

Employees: 67
Headquarters: DUBLIN
Listed: Dec 21, 2012
Sector: Health Care
Industry: Biotechnology
Website: prothena.com

Leadership

Prothena executives
Name	Title	Since	Age
Daniel Welch	—	—	67
Lars Ekman	—	—	75
Gene Kinney	—	2012	56
Tran Nguyen	—	—	51
Brandon Smith	—	—	50
Karin Walker	—	—	61
Wagner Zago	—	—	52
Chad Swanson	—	—	53
Michael Malecek	—	—	59
Paula Cobb	—	—	52
Richard Collier	—	—	71
Shane Cooke	—	—	62
William Dunn	—	—	55
Helen Kim	—	—	62
Dennis Selkoe	—	—	81

Revenue by product and region

Fiscal year ended Dec 31, 2025: $9.68M total revenue

By product

Collaboration revenue$9.63M99.5%
Revenue from license and intellectual property$50.00K0.5%

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Prothena suppliers and customers
Company	Relationship	Country	Correlation
Catalent CTLT	Supplier and customer	US	0.88
Perrigo PRGO	Supplier and customer	IE	0.71
Roche Holding ROG.SW	Supplier and customer	CH	-0.23
Novo Nordisk B	Supplier and customer	DK	-0.43
Bristol-Myers Squibb BMY	Supplier and customer	US	-0.61
biOasis Technologies BTI.TO	Supplier and customer	US	—
AAIPharma Inc. AAIIQ.XX1	Supplier and customer	US	—
Berkshire Sterile Manufacturing, Inc.	Supplier and customer	US	—
C.H. Boehringer Sohn AG & Co. KG	Supplier and customer	DE	—
University of California	Supplier and customer	US	—

Similar companies

Companies in the same industry as Prothena

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.